fashion -WSS

fashion

author：explore 2025-10-02 03:11:07 Page View：19822

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： NVIDIA and Google execs on the future of AI and drug discovery
Next article： Duchenne breakthrough therapy leaves behind pioneering families

leisure time

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Gene therapy’s promise and the high cost of hope

AdobeAtthebustlingChicagoO’Hareairport,myluggageandIcollidedwithanelderlycouple.MyheartsankwhenIreal

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Addiction experts warn against a second 'war on drugs'

STAT'sLevFacher(left)spokewiththreeaddictionexperts—(fromleft)BraunzCourtney,KeithHumphreys,andAyesh